- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05627323
CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma
A Phase 1b Study to Evaluate CHM-1101, a CAR T-Cell Therapy With a Chlorotoxin Tumor-Targeting Domain for Patients With Matrix Metallopeptidase 2 Positive (MMP2+) Recurrent or Progressive Glioblastoma Multiforme
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a phase 1b, multicenter, feasibility/safety study of the dual delivery (administered through both intracavitary/intratumoral [ICT] and intraventricular [ICV] catheters) of CHM-1101, an autologous chlorotoxin-chimeric antigen receptor (CLTX-CAR) cell product, in participants with recurrent or progressive GBM. The investigational product is identified as CHM-1101 (CLTX(EQ)28ζ/CD19t+ CAR T cells).
PRIMARY OBJECTIVE
• To determine the recommended phase 2 dose (RP2D) for dual ICT and ICV delivery of CHM-1101 in participants with MMP2+ recurrent or progressive GBM.
SECONDARY OBJECTIVES
- To assess the feasibility and safety of dual delivery of CHM-1101.
- To describe the persistence, expansion, immunogenicity, and phenotype of CHM-1101 and endogenous cells tumor cyst fluid (TCF), peripheral blood (PB), and cerebrospinal fluid (CSF).
In participants who receive at least 2 of the 3 planned doses of CHM-1101 in Cycle 1:
- Estimate the progression-free survival (PFS) rates
- Estimate the overall survival (OS) rates
- To evaluate the disease response rate.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Chimeric Therapeutics
- Phone Number: 1-866-430-1081
- Email: clinicaltrials@chimerictherapeutics.com
Study Locations
-
-
California
-
Duarte, California, United States, 91010
- Not yet recruiting
- City of Hope Medical Center
-
Contact:
- Cara Nolan
- Phone Number: 626-825-7996
-
Principal Investigator:
- Behnam Badie
-
-
Texas
-
Austin, Texas, United States, 78704
- Recruiting
- St. David's South Austin Medical Center - Sarah Cannon - Austin
-
Contact:
- Araviad Ramakrishnan, MD
- Email: araviad.ramakrishnan@hcahealthcare.com
-
Principal Investigator:
- Araviad Ramakrishnan, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Documented informed consent of the subject and/or legally authorized representative.
- Agreement to allow the use of archival tissue from diagnostic tumor biopsies.
- Age 18 years and older.
- ECOG status of 0 or 1.
- Life expectancy ≥12 weeks.
- Subject has a prior histologically confirmed diagnosis of a grade 4 glioblastoma multiforme (GBM) or a prior histologically confirmed diagnosis of a grade 2 or 3 malignant glioma and now has radiographic progression consistent with a grade 4 GBM (IDH wild type), grade 4 diffuse astrocytoma (IDH mutant), or has a unifocal relapse of GBM.
- Relapsed disease: radiographic evidence of recurrence/progression of measurable disease after standard therapy and ≥ 12 weeks after completion of front-line radiation therapy.
- Confirmed MMP2+ tumor expression by IHC (≥20% moderate/high MMP2 score [2+ or 3+]).
- Adequate venous access to perform leukapheresis.
- No known contraindications to leukapheresis or steroids.
- In-range baseline laboratory values for WBC (>2000/dL [or ANC ≥1000/mm^3]), platelets (≥75000/mm^3), total bilirubin (≤1.5xULN), AST (≤2.5xULN), ALT (≤2.5xULN), serum creatinine (≤1.5xmg/dL), and oxygen saturation (≥95% on room air)
- Seronegative for human immunodeficiency virus (HIV) by antigen/antibody (Ag/Ab) testing.
- Seronegative for hepatitis B and/or hepatitis C virus.
- Women of childbearing potential must have a negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test is required.
- Agreement by women AND men of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 3 months after the last dose of CHM-1101. (Childbearing potential is defined as not being surgically sterilized (women and men) or, for women, having not been free from menses for > 1 year.)
Exclusion Criteria:
- Within 3 months of having received prior bevacizumab therapy at the time of enrollment.
- Not yet recovered from toxicities of prior therapy.
- Uncontrolled seizure activity and/or clinically evident progressive encephalopathy.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent.
- Clinically significant uncontrolled illness.
- Active infection requiring antibiotics.
- Known history of HIV or hepatitis B or hepatitis C infection.
- Other active malignancy.
- Women only-pregnant or breastfeeding.
- Any other condition that would, in the Investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns with clinical study procedures.
- Prospective subjects who, in the opinion of the Investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (CAR T cell therapy) 1
Arm 1 participants will undergo resection of their tumor. Participants receive half the CHM-1101 dose via Rickham catheters into the tumor cavity and half into the lateral ventricle. Cycle 1 (28 days) CHM 1101 total dose will be divided across 3 once-weekly administrations. After Cycle 1, additional cycles may be initiated in the absence of disease progression or unacceptable toxicity provided that the principal investigator and participant agree to continue and if adequate autologous CAR-T doses remain. |
Administered via ICT/ICV dual delivery
Other Names:
|
Experimental: Treatment (CAR T cell therapy) 2
Arm 2 participants will undergo resection of their tumor. Participants receive half the CHM-1101 dose via Rickham catheters into the tumor cavity and half into the lateral ventricle. Cycle 1 (28 days) CHM 1101 total dose will be divided across 3 once-weekly administrations. After Cycle 1, additional cycles may be initiated in the absence of disease progression or unacceptable toxicity provided that the principal investigator and participant agree to continue and if adequate autologous CAR-T doses remain. |
Administered via ICT/ICV dual delivery
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose-limiting toxicity (DLT)
Time Frame: 28 days
|
Assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0.
|
28 days
|
Cytokine Release Syndrome (CRS)
Time Frame: up tp 15 years
|
Assessed per American Society for Transplantation and Cellular Therapy (ASTCT) consensus grading guideline, evaluating levels and phenotype detected in tumor cyst fluid (TCF), peripheral blood (PB), and cerebrospinal fluid (CSF) (absolute number per µL by flowcytometry).
|
up tp 15 years
|
All other adverse events and toxicities
Time Frame: up to 15 years
|
Assessed per NCI CTCAE v5.0.
|
up to 15 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Chimeric antigen receptor (CAR) T cell
Time Frame: up to 15 years
|
Assess levels and phenotype detected in tumor cyst fluid (TCF), peripheral blood (PB), and cerebrospinal fluid (CSF) (absolute number per µL by flowcytometry).
|
up to 15 years
|
Endogenous T cell
Time Frame: up to15 years
|
Assess level and phenotype detected in TCF, PB, and CSF (absolute number per µL by flowcytometry).
|
up to15 years
|
Human anti-CAR antibody (HACA)
Time Frame: up to 15 years
|
Serum samples will be evaluated for HACA against the CLTX(EQ)28ζ therapeutic agent.
|
up to 15 years
|
Progression free survival (PFS) time
Time Frame: 12 months
|
Measured from the date of first infusion of CAR-T cells until the first date when progressive disease (PD) is objectively documented or death from any cause, whichever is earlier.
|
12 months
|
Overall survival (OS)
Time Frame: up to 15 years
|
Measured from the date of first infusion of CAR-T cells until death.
|
up to 15 years
|
Disease response
Time Frame: 12 months
|
Assessed by modified Response Assessment in Neuro-Oncology Criteria (RANO) criteria.
|
12 months
|
Clinical benefit rate
Time Frame: 12 months
|
The proportion of participants who experience a complete response, a partial response, or stable disease that is 3 months or greater in duration.
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Jason Litten, MD, Chimeric Therapeutics
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHM-1101-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glioblastoma Multiforme of Brain
-
University Hospital, GenevaActive, not recruitingGlioblastoma Multiforme | Glioblastoma Multiforme of Brain | Glioma of Brain | Glioblastoma, AdultSwitzerland
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Recurrent Glioblastoma | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of Brain | Astrocytoma of Brain | Astrocytoma, MalignantUnited States, Germany, Netherlands, Switzerland, Belgium
-
Milton S. Hershey Medical CenterRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
-
Milton S. Hershey Medical CenterNational Cancer Institute (NCI)RecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
-
Mashhad University of Medical SciencesUnknownEfficacy of Two Temozolomide Regimens in Adjuvant Treatment of Patients With Brain High Grade GliomaGlioblastoma Multiforme of Brain | Anaplastic Astrocytoma of BrainIran, Islamic Republic of
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States, Belgium, Switzerland, Germany, Netherlands
-
TVAX BiomedicalFDA Office of Orphan Products DevelopmentRecruitingGlioblastoma Multiforme of BrainUnited States
-
Shenzhen Geno-Immune Medical InstituteEnrolling by invitationGlioblastoma Multiforme | Glioblastoma Multiforme of BrainChina
-
University of Roma La SapienzaCompletedGlioblastoma Multiforme of Brain
-
Imperial College LondonRecruitingGlioblastoma Multiforme of BrainUnited Kingdom
Clinical Trials on CHM-1101 CAR-T cells
-
Chimeric TherapeuticsNot yet recruitingGastric Cancer | Colorectal Cancer | Neuroendocrine Tumors
-
Southwest Hospital, ChinaUnknownLymphoma, Large B-Cell, DiffuseChina
-
Medical College of WisconsinChildren's Hospital and Health System Foundation, WisconsinCompletedLymphoma, B-Cell | Lymphoma, Non-Hodgkin | Chronic Lymphocytic Leukemia | Small Lymphocytic LymphomaUnited States
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingMultiple Myeloma | New Diagnosis TumorChina
-
Peking University People's HospitalNot yet recruitingT-cell Non-Hodgkin's Lymphoma
-
Zhejiang UniversityYake Biotechnology Ltd.Not yet recruitingAcute Myeloid LeukemiaChina
-
University College, LondonEnrolling by invitationMultiple MyelomaUnited Kingdom
-
Wuhan Sian Medical Technology Co., LtdWuhan Union Hospital, China; Xiangyang Central Hospital; Jingzhou Central Hospital and other collaboratorsUnknownB Cell Lymphoma | Acute Lymphoblastic LeukemiaChina
-
Medical College of WisconsinChildren's Hospital and Health System Foundation, WisconsinRecruitingAcute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia Recurrent | Acute Lymphoblastic Leukemia With Failed Remission | Acute Lymphoblastic Leukemia Not Having Achieved RemissionUnited States
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingNon-hodgkin Lymphoma,B CellChina